Cystatin C as a Predictor of Renal Function and Methotrexate-Associated Toxicities in Patients With Rheumatoid Arthritis
Authors' conclusion
Our results showed that eGFR based on SCr was overestimated compared with eGFR based on cystatin C. In addition, we demonstrated that MTX-associated toxicities were significantly increased in the group with a changed stage when the eGFR was converted from CKD-EPISCr to CKD-EPIcys.
Study context
- Population
- Patients with rheumatoid arthritis (RA)
- Participants
- 436 patients
- Exposure
- Estimated glomerular filtration rate (eGFR) by CKD-EPI cystatin C vs CKD-EPI serum creatinine
- Outcome
- Discrepancy in eGFR using serum creatinine (SCr) vs cystatin C, and MTX-associated toxicities
Main finding
As reported in the abstract
Mean eGFR by CKD-EPI equation
- Reclassified to a higher KDIGO CKD stage after converting to CKD-EPIcys
- 29.8%
- Of eGFR > 50 mL/min/1.73 m², reclassified to eGFR 10-50 requiring methotrexate (MTX) dose adjustment
- 6.4%
Observational data: associations, not effects.
Safety
MTX-associated toxicities (anemia, leukopenia, nephrotoxicity)
- Incidence significantly higher in CKD stage-changed than nonstage-changed
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Cystatin C as a Predictor of Renal Function and Methotrexate-Associated Toxicities in Patients With Rheumatoid Arthritis. J Rheumatol. Published 1 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →